Plasma Dephosphorylated-Uncarboxylated Matrix Gla-Protein in Systemic Sclerosis Patients: Biomarker Potential for Vascular Calcification and Inflammation.

Autor: Potjewijd J; Department of Internal Medicine, Division Clinical and Experimental Immunology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands., Tobal R; Department of Internal Medicine, Division Clinical and Experimental Immunology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands., Boomars KA; Department of Respiratory Medicine, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands., van Empel VVPM; Department of Cardiology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands., de Vries F; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6211 LK Maastricht, The Netherlands., Damoiseaux JGMC; Central Diagnostic Laboratory, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands., Schurgers LJ; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, 6211 LK Maastricht, The Netherlands., van Paassen P; Department of Internal Medicine, Division Clinical and Experimental Immunology, Maastricht University Medical Center, 6229 HX Maastricht, The Netherlands.
Jazyk: angličtina
Zdroj: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2023 Nov 24; Vol. 13 (23). Date of Electronic Publication: 2023 Nov 24.
DOI: 10.3390/diagnostics13233526
Abstrakt: Background: Systemic sclerosis (SSc) patients face an elevated risk of cardiovascular disease (CVD), even when classic cardiovascular risk factors are considered. Plasma dephosphorylated-uncarboxylated Matrix Gla-protein (dp-ucMGP), an inactive form of MGP, is associated with increased CVD risk. Smooth muscle cells, implicated in SSc's development, are the primary dp-ucMGP producers. This study assessed dp-ucMGP levels and initial CVD events in early-diagnosed SSc patients, investigating its potential as a CVD and all-cause mortality predictor over time.
Methods: In a cohort of 87 SSc patients (excluding those with pre-existing CVD or on dialysis), baseline dp-ucMGP levels were measured, along with cardiovascular risk factors. Validation involved assessing dp-ucMGP in a subset of treatment-naive SSc patients.
Results: A significantly elevated median dp-ucMGP level of 634 pmol/L (IQR 301) compared with healthy controls (dp-ucMGP < 393 pmol/L; p < 0.001) was observed. Validation in a treatment-naive SSc patient subset yielded similar results (median 589 pmol/L; IQR 370). During a median 10.5-year follow-up among 78 SSc patients, 33.3% experienced their first CVD event, independent of traditional risk factors. Elevated dp-ucMGP levels (>634 pmol/L) correlated with a higher risk of CVD and/or death (log-rank test: p < 0.01).
Conclusions: In summary, dp-ucMGP emerges as a novel biomarker in SSc patients, with elevated levels indicating an increased risk of CVD and/or mortality in this population.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje